P0747 - Incidence and Prevalence of Gynecological Cancers in Women With IBD: A Large Population-Based Study

Osama Hamid, MD, MRCPI¹, Ahmed Eltelbany, MD, MPH¹, Khaled Alsabbagh Alchirazi, MD¹, Khalid K. Ahmed, MD², Rama Nanah, MD¹, Miguel Regueiro, MD^3
1Cleveland Clinic, Cleveland, OH; ²The Wright Center for GME, Scranton, PA; ³Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH

Introduction: Inflammatory bowel disease (IBD) may increase the risk of extraintestinal malignancies. The relationship between gynecological cancers and IBD remains unclear. This study aims to investigate the epidemiology and characteristics of gynecological cancers in women with IBD, to better understand this potential association and its implications.

Methods: Using TrinetX, a multi-institutional database, we identified adult women diagnosed with IBD between 2012-2022. We also identified concurrent or subsequent diagnoses of gynecological cancers, specifically ovarian, uterine, cervical and vulvar cancers. We excluded patients with a history of gynecological cancers prior to their IBD diagnosis. The prevalence and incidence rate (person-year) of gynecological cancers in IBD were calculated. The baseline characteristics of patients with gynecological cancers and IBD were compared to those with gynecological cancers without a history of IBD, after adjustment for age, race, co-morbidities including diabetes mellitus, hypertension, obesity, HIV, smoking, polycystic ovary syndrome, family history of gynecological cancers and IBD medications.

Results: Among the 264,984 women with IBD in our database, 4,563 (1.7%) developed gynecological cancer. Demographic and co-morbid condition details for the cohorts are presented in Table 1. Comparing the IBD population to the non-IBD general population, we observed a higher incidence proportion per year and prevalence of all four types of gynecological cancers. For cervical cancer, the annual incidence proportion was 0.033% among women with IBD, while it was 0.014% in non-IBD patients. In ovarian cancer, the annual incidence was 0.042% in the IBD group, compared to 0.0209% in non-IBD patients. Endometrial cancer showed an annual incidence proportion of 0.047% in women with IBD, compared to 0.0279% in non-IBD patients. Similarly, vulvar cancer had an annual incidence proportion of 0.012% in IBD patients, compared to 0.0038% in non-IBD patients. Figure 1 illustrates the 10-year (person-year) prevalence rate for each specific gynecological cancer.

Discussion: Our study indicates that women with IBD have a nearly two- to three-times higher incidence and prevalence of gynecological cancers compared to the general population. These results emphasize the significance of implementing regular gynecological cancer screening and surveillance protocols in IBD patients. Further studies are needed to understand the mechanisms for these cancers and to develop preventive strategies.




Disclosures:


Osama Hamid, MD, MRCPI¹, Ahmed Eltelbany, MD, MPH¹, Khaled Alsabbagh Alchirazi, MD¹, Khalid K. Ahmed, MD², Rama Nanah, MD¹, Miguel Regueiro, MD³. P0747 - Incidence and Prevalence of Gynecological Cancers in Women With IBD: A Large Population-Based Study, ACG 2023 Annual Scientific Meeting Abstracts. Vancouver, BC, Canada: American College of Gastroenterology.